Text Size

Detection and Characterisation of Varicella Zoster Virus From Dermal Lesions of Chickenpox-infected Patients

This study has been completed.
Sponsor:
Information provided by:
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00127608
First received: August 4, 2005
Last updated: September 29, 2011
Last verified: September 2011
History of Changes
  Purpose

This study is conducted in order to collect clinical samples from patients who are diagnosed of having chickenpox infection. The results of this study will provide basic scientific information about chickenpox disease.


Condition Intervention Phase
Chickenpox
 Biological: Chickenpox infection
 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: An Open, Prospective, Non-prophylactic, Non Therapeutic Study for the Detection and Characterisation of Varicella Zoster Virus Collected From Dermal Lesions of Patients Who Are Diagnosed of Having Varicella

Resource links provided by NLM:

MedlinePlus related topics: Chickenpox Shingles
U.S. FDA Resources

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • VZV DNA per clinical sample collected

Study Start Date: June 2005
Primary Completion Date: July 2006 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: Chickenpox infection
    Other Name: Chickenpox infection
Detailed Description:

The study involves NO therapeutic or prophylactic treatment nor further observation of the patients. There is no product to be tested in this study.

  Eligibility

Ages Eligible for Study:   up to 16 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Pediatric patients who are diagnosed of having varicella and are presenting varicella dermal lesions.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00127608

Locations
Czech Republic
GSK Investigational Site
Praha 8, Czech Republic, 180 81
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT00127608     History of Changes
Other Study ID Numbers: 103815
Study First Received: August 4, 2005
Last Updated: September 29, 2011
Health Authority: Czech Republic: State Institute for Drug Control

Additional relevant MeSH terms:
Chickenpox
Herpes Zoster
Herpesviridae Infections
DNA Virus Infections
Virus Diseases

ClinicalTrials.gov processed this record on May 19, 2013